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https://doi.org/10.1016/j.stemcr.2018.04.023Human breast cancers referred to as ‘‘basal-like’’ are of interest
because they lack effective therapies and their biology is poorly
understood. The term basal-like derives from studies demon-
strating tumor gene expression profiles that include some tran-
scripts characteristic of the basal cells of the normal adult human
mammary gland and others associated with a subset of normal
luminal cells. Elucidating the mechanisms responsible for the pro-
files of basal-like tumors is an active area of investigation. More
refined molecular analysis of patients’ samples and genetic strate-
gies to produce breast cancers de novo from defined populations
of normal mouse mammary cells have served as complementary
approaches to identify relevant pathway alterations. However,
both also have limitations. Here, we review some of the underlying
reasons, including the unifying concept that some normal luminal
cells have both luminal and basal features, as well as some
emerging new avenues of investigation.Introduction
Remarkable technical advances are improving our under-
standing of normal human breast biology and the identifi-
cation of perturbed pathways and mutations implicated in
their transformation. Nevertheless, a lack of effective treat-
ments for disseminated breast cancer remains a huge global
problem. Scrutiny of this conundrum reveals multiple
potential explanations. These include numerous gaps of
knowledge in the normal biology of the human mammary
gland, how it develops, and the molecular mechanisms
that control its growth, differentiation, hormone respon-
siveness, and aging. Another major issue is the extensive
heterogeneity in the genetic and biological properties of
the malignant cells evident in most patients’ breast cancers
already at diagnosis, and their subsequent continuing evo-
lution (Beca and Polyak, 2016; Turashvili and Brogi, 2017).
This diversity, both within and between individual breast
cancers, and the limited amount of tissue available for anal-
ysis create important challenges todrawing retrospective in-
ferences about the cellular and molecular processes leading
to the generation of any individual malignant population.
These concerns apply in particular to molecular analyses
thatmay examine changes in entire genomes and transcrip-
tomes, but are generally derived from extracts of bulk popu-
lations. Evenwhen thesemethods are applied to single cells,
the numbers that can currently be analyzed may preclude
detection of cell types responsible for perpetuating tumor
growth present at frequencies of <1/103 cells (Luo et al.,
2015; Wei and Lewis, 2015). In addition, they do not1676 Stem Cell Reports j Vol. 10 j 1676–1686 j June 5, 2018 j ª 2018 The A
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to sampling issues. Classical histopathology offers great res-
olution of spatial features of tissue samples and cell-based
measurements of markers that distinguish different normal
cell types. However, classical histopathology is also limited
in the number of markers that can be examined and an
inability to identify functional cell output properties.
The common persistence of recognized features of the
tissue of origin of many tumors makes it likely that the spe-
cific cell type fromwhich tumors arisemight be expected to
contribute some consistent vulnerable features to their
transformed derivatives. This concept underlies continued
research interest in assessing and exploiting this possibility.
One attractive strategy has been to createmice that develop
genetically engineered breast cancers from specific cell
types for which unique gene expression features have
been identified. Ever increasing improvements in the types
of molecular manipulations available for this purpose are
now adding impressive power and precision to this forward
genetic approach. However, the notable differences in the
structure and regulation of mouse and human mammary
cells pose limitations on what can be extrapolated from
mouse models (Cardiff et al., 2017). In addition, relating
the relevance of mouse mammary tumor models to their
human counterparts requires extensive clinical experience.
Here, we focus a discussion of these issues with respect to
a particular group of poor prognosis human breast cancers
within those historically classified pathologically as ‘‘triple-
negative’’ due to the lack of expression of estrogen recep-
tors (ER), progesterone receptors (PR), and human
epidermal growth factor receptor 2 (HER2). The group of
interest is referred to as ‘‘basal-like’’ to accommodate the
confusing finding in them of transcripts associated with
both luminal and basal cells of the normal gland.Definitions
Definitions are the foundation of science in general and
biology in particular. Nowhere is there more truth in this
statement than in the complex fields of normal tissue
development and experimental and applied oncology. We
have therefore elected to begin with the definitions used
here for several terms relevant to the issues discussed
because they have been a frequent source of confusion in
the literature.uthor(s).
ns.org/licenses/by/4.0/).
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In mice, the term ‘‘mammary gland’’ is commonly used to
refer to both the mammary epithelial cells as well as their
surrounding supporting tissues. In humans, the corre-
sponding structure is usually referred to as the ‘‘breast.’’
Here, we use the terms ‘‘mammary’’ and mammary gland
in the context of normal tissue in both species to refer
exclusively to the epithelial cells that are encased within
the basement membrane.
Tumor, Neoplasia, and Cancer
The lack of a precise definition of malignancy (Hanahan
and Weinberg, 2011) becomes particularly important in
studies that seek to track and characterize the genesis
and evolution of transformed populations. The term ‘‘tu-
mor’’ applies to any lump created by an abnormal accu-
mulation of cells and is also called a neoplasm. Such
abnormal growth can then be further classified as benign
or malignant. Here, we reserve use of the term ‘‘cancer’’
to refer to mammary cell populations that can be seen
to display abnormal invasive and/or metastatic activity.
However, we recognize that this may pose a difficulty to
the assessment of some mouse tumor models when ani-
mals have to be sacrificed before the tumors generated
have begun to display detectable invasive or metastatic
properties. In such situations, an expert pathology
opinion may be useful to identify cytological features
that are known to be associated with malignant activity
in human breast cancers.
Basal and Myoepithelial
The term ‘‘basal’’ was first introduced to refer to cells in
normal multi-layered epithelia that are juxtaposed next
to the stroma and/or the basement membrane. It has also
been used to refer to cells that are similarly positioned in
a benign or malignant lesion. In the mammary glands of
adult mice and humans, most of the basal cells have fea-
tures of smooth muscle cells. These include the presence
of contractile proteins (such as myosin and smoothmuscle
actin [SMA]) that enable the gland to express the milk pro-
duced during lactation down the ducts and out the
nipple—hence the alternate description of basal mammary
cells as ‘‘myoepithelial’’ cells (Linzell, 1952).
It should be noted, however, that histological sections of
the normalmammary gland showing cells containing SMA
as appearing to form a continuous layer, does not mean
that all of the cells in the basal layer have identical func-
tions or proliferative potential. Indeed, over 30 years ago
a population of ‘‘basal-clear cells’’ that appeared less differ-
entiated than most of the myoepithelial cells of the basal
layer was identified in electron micrographs of the human
mammary gland, and the fact that these cells had both
epithelial (luminal-like) and myoepithelial features, led
the authors to propose that they might be precursors of
myoepithelial cells (Smith et al., 1984).Basal-like
The term ‘‘basal-like’’ was introduced in 2001 (Sorlie et al.,
2001) to refer to a group of human breast cancers that share
an RNA signature that includes a high expression of cyto-
keratins 5 and 17 (CK5 and CK17), laminin, and fatty acid
binding protein 7; i.e., proteins found in basal cells but
not luminal cells of the normal human mammary gland.
However, this designation is not intended to infer an origin
of basal-like tumors from a myoepithelial cell nor a lack of
expression of genes associated with luminal cells.
Cell Types in the Normal Human Mammary Gland
Most cancers are thought to represent clonally derived pop-
ulations that have acquired intrinsically determined
changes in mechanisms controlling the biology of the
normal tissue in which a given cancer arises. There is
thus much interest in understanding the different cell
types that constitute the normal adult human mammary
gland and the mechanisms that control their production,
differentiation, and loss, as a basis for elucidating the con-
sequences of their perturbation that lead to the genesis of
human breast cancers.
The normalmammary gland in adult female humans and
mice is a continuous bilayered epithelial structure consist-
ing of branching ducts originating from a central duct and
terminating in alveolae. The inner and outer cell layers are
referred to as luminal and basal, respectively. The cells
within each layer express many proteins, some shared,
some distinct, and some notably promiscuous (see Tables
1 and 2) (Gusterson et al., 2005; Gusterson and Stein,
2012; Howard and Gusterson, 2000). Expression of certain
CKs that distinguish cells in the luminal and basal layers
of the adultmammary gland have thus been usefulmarkers
of these cells, albeit with some notable exceptions. For
example, CK8 andCK18 appear to be consistently exclusive
to luminal cells, but CK5 and CK14, despite their frequent
designation as basal keratins, are also seen in the luminal
cells of the terminal ductal lobular units (TDLUs) of the
normal human mammary gland (Gusterson et al., 2005;
Gusterson and Stein, 2012; Santagata et al., 2014). In
contrast, CK5 and CK14 are not expressed in any luminal
cells in the adult mouse mammary gland, although scat-
tered CK14+ (but not CK5+) luminal cells have been identi-
fied in the developing mouse mammary gland prior to the
onset of puberty (Mikaelian et al., 2006). The shared expres-
sionofCK5 andCK14 in adult human, butnotmouse, basal
and TDLU luminal cells is of particular relevance because
TDLUs have been implicated as a frequent physical site of
origin of human breast cancers (Gusterson, 2009; Guster-
son et al., 2005; Wellings et al., 1975).
Many additional features and functional properties of
normal adult human (and mouse) mammary cells have
also now been identified. Most of these have usedStem Cell Reports j Vol. 10 j 1676–1686 j June 5, 2018 1677
Table 1. Markers Used to Characterize Different Human Mammary Luminal and Basal Cells by Immunohistochemistry
Antigen Staining Pattern Antibody (Source and Clone Name)
CK5/6 strong staining of myoepithelial cells in ducts
sometimes variable staining of cells in TDLU (loss of myoepithelial staining)
no staining of myofibroblasts
staining of luminal cells in some benign conditions
reduced or occasionally negative in DCIS-myo
mouse MAb D5/16B4
CK14 strong staining of myoepithelial cells in ducts
sometimes variable staining in TDLU (loss of myoepithelial staining)
no staining of myofibroblasts
staining of luminal cells in some benign conditions
reduced or occasionally negative in DCIS-myo
rabbit MAb SP53
Myosin heavy chain strong staining of normal myoepithelial cells
no staining of myofibroblasts
no staining of luminal cells
can be negative in DCIS-myo in 10% cases
mouse MAb SMMS-1
P63 strong nuclear staining of all normal myoepithelial cells
does not stain myofibroblasts or luminal cells
retained in DCIS-myo
mouse MAb 4A4
CK8 and CK18 strong staining of luminal epithelial cells
maintained in benign conditions
no staining of myoepithelial cells or myofibroblasts
mouse MAb B22.1 and B23.1
ER strong staining of a subpopulation of luminal epithelial cells
no staining of myoepithelial cells or of myofibroblasts
rabbit MAb SP1
PR strong staining of a subpopulation of luminal epithelial cells
no staining of myoepithelial cells or of myofibroblasts
rabbit MAb 1E2
CK, cytokeratin; MAb, monoclonal antibody; TDLU, terminal ductal lobular unit; DCIS, ductal carcinoma in situ; myo, myoepithelial.
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methods to isolate different subsets in a viable state based
on their differential expression of surface markers that
distinguish basal and luminal cells in fixed tissue (Eirew
et al., 2010; O’Hare et al., 1991; Visvader and Stingl,
2014). These typically exploit the expression of CD44
(also referred to as HERMES), CD90 (THY1), or CD10 (a
neutral endopeptidase, also referred to as CALLA for com-
mon lymphocyte-associated antigen) on the surface of
basal/myoepithelial cells as compared with luminal cells
and the expression of CD326 (epithelial cell adhesion
molecule [EpCAM]) or CD24 (heat stable antigen) or
CD133 (Prominin 1) on the surface of luminal cells as
compared with human basal/myoepithelial cells.
In addition, human luminal cells can be further subdi-
vided based on their co-expression of CD49f (a6 integrin,
originally thought to be an exclusive marker of basal
cells) and KIT (the receptor for stem cell factor, also
known as KIT-ligand). The human CD49f+KIT+ luminal
(EpCAM+CD24+CD133+) cells thus obtained display quite
different molecular features and functional properties
than the luminal cells that are CD49f and KIT. These
include differences in expression of epidermal growth fac-1678 Stem Cell Reports j Vol. 10 j 1676–1686 j June 5, 2018tor receptors (EGFR), which are higher on the CD49f+ sub-
set of luminal cells (Pellacani et al., 2016; Visvader and
Stingl, 2014), and are coupled with a selective ability to
proliferate in response to EGF stimulation (in concert
with other factors) in vitro, a property shared with some
CD49f+ basal cells (Kannan et al., 2013, 2014). Interest-
ingly, the CD49f+EpCAM+ luminal cells generate only
progeny with features of luminal cells, whereas the
CD49f+ basal cells make both basal and luminal progeny
(Raouf et al., 2008). However, it remains unknown as to
whether these differentiation potentialities of normal
adult human mammary luminal progenitors are similarly
restricted in vivo.
Comparisons of the human luminal progenitor-contain-
ing and basal subsets have shown that EGFR is expressed at
higher levels on the former (Monaghan et al., 1995), and
bilineage mammary gland regenerative potential in trans-
planted immunodeficient mice is exclusive to the latter
(Eirew et al., 2008; Lim et al., 2009; Nguyen et al.,
2014b). Human luminal cells in the progenitor-enriched
fraction are also distinct from basal cells in their possession
of very short telomeres, sufficient to initiate a DNA damage
response (Kannan et al., 2013; Kurabayashi et al., 2008).
Table 2. Markers Used to Isolate Different Subsets of Viable Human Mammary Cells
Surface Marker Staining Pattern
Antibody (Source
and Clone Name)
Antigens Expressed on Basal Cells
Integrin a6
CD49f
prominent staining of two populations of cells—one (referred to as basal cells) that expresses
other features of basal cells and low or no detectable staining of cells with luminal features
the other expresses higher levels of markers of luminal cells (EpCAM/CD24/AC133, etc.) and is
considered part of the luminal population (see below)
commonly used to selectively isolate all mammary cells that generate colonies in vitro
pure or mixed myoepithelial cells ± luminal cells in vitro and bilayered glands regenerated
in vivo are derived exclusively from CD49f+ cells that lack luminal markers
rat MAb
GOH3
CALLA
CD10
overlapping positive and negative staining with CD49f staining pattern mouse MAb
HI10A
THY1
CD90
overlapping positive and negative staining with CD49f staining pattern mouse MAb
5E10
HERMES
CD44
overlapping positive and negative staining with CD49f staining pattern
also used as a putative positive marker of breast cancer stem cells
mouse MAb
BJ18
Antigens Expressed on Luminal Cells
EpCAM
CD326
prominent staining of two populations of cells—one (referred to as luminal cells) that
expresses other features of luminal cells and low or no detectable staining of cells with basal
features
the other (referred to as luminal progenitors) expresses higher levels of markers of basal cells
(CD49f/CD10/CD90/CD44, etc.), is exclusively KIT+ and contains all cells that generate
colonies of exclusively luminal cells in vitro
mouse MAb
9C4
HSA
CD24
overlapping positive and negative staining with EpCAM staining pattern
also used as a putative negative marker of breast cancer stem cells within the CD44+ population
mouse MAb
32D12
Prominin
CD133
overlapping positive and negative staining with EpCAM staining pattern Mouse MAb
AC133
MUC1
CD
overlapping positive and negative staining with EpCAM staining pattern Mouse MAb
214D4
KIT
CD117
overlapping positive and negative staining with CD49f staining within the EpCAM+ population Mouse MAb
104D2
MAb, monoclonal antibody.
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higher levels of reactive oxygen species, which results in
their accumulation of detectable oxidative DNA damage
(Kannan et al., 2014). Comprehensive epigenomic and
deep global transcriptome data further underscore the bio-
logic differences exhibited by these three phenotypes of
normal human mammary cells: i.e., EpCAM+ luminal cells
with and without surface CD49f, and EpCAM basal cells
that are also CD49f+ (Kannan et al., 2013; Lim et al.,
2009; Pellacani et al., 2016; Raouf et al., 2008).
In mice, the first mammary cells to arise in the embryo
exhibit features of adult mouse mammary basal cells (Ma-
karem et al., 2013b; Spike et al., 2012). Only later, around
the time of birth, do cells with distinct luminal programs
become apparent. The mouse mammary gland then be-
comes similar to the adult human gland in its content ofdistinct subsets of basal cells, with and without clonogenic
properties, and an analogous subdivision of the luminal
compartment into non-clonogenic luminal cells, as well as
a phenotypically separable subset with some properties
of basal cells and luminal clonogenic activity in vitro
(Makarem et al., 2013a, 2013b). In the mouse, there is also
now strong evidence that some luminal cells in the adult
mammary gland display long-term lineage-restricted self-
sustaining ability in vivo (Wang et al., 2017; Wuidart et al.,
2016).
Molecular Identification of Human Basal-like Breast
Cancers
Human breast cancers are classified histologically on the
basis of gross morphological and microscopic features.
Prognostic accuracy is further improved by assessingStem Cell Reports j Vol. 10 j 1676–1686 j June 5, 2018 1679
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abnormalities, especiallywhen these features are combined
with an assessment of the extent of tumor spread (Green
et al., 2016). These criteria are not predictive of specific
treatment outcomes, apart from the extent of surgery
and/or radiotherapy. Clinical trials involving thousands
of patients have established the utility of defined anti-
bodies that detect ER and PR, as well as HER2 in tissue
sections of patients’ breast cancers using appropriate end-
points, thus enabling the identification of patients likely
to benefit from endocrine or Herceptin therapy. However,
there remains a recognized 15%–20% variability in the
immunohistochemical (IHC) results obtained in different
major clinical centers (McCullough et al., 2014), underscor-
ing the problem inherent in the use of these markers for
tumor classification.
In 2000, Perou and colleagues reported the ability of
more objective and comprehensive global RNA expression
analyses to subdivide breast cancers into five different sub-
groups (Perou et al., 2000). These were named normal-like,
luminal A, luminal B, HER2/ERB2-enriched, and basal-like,
reflecting similarities with transcript profiles and protein
properties available for normal human luminal and basal
mammary cells. This report was welcomed as the begin-
ning of a new era of more objective molecular diagnostics
in breast cancer, and, within 4 years, a first molecular test
exploiting this approach (Oncotype DX) was introduced
clinically (Cronin et al., 2004). Eighteen years later, it is
interesting to reflect that analyses of samples of breast can-
cer tissue from 42 individuals in the original paper (Perou
et al., 2000) and 115 cases a year later (Sorlie et al., 2001)
were sufficient to identify five major groups of breast can-
cers with significantly different survival expectations using
available therapies. Now, the same degree of prognostic
accuracy can be obtained using a 50-gene expression assay
(PAM50) (Nielsen et al., 2014; Parker et al., 2009). These
findings thus continue to stimulate interest in identifying
clinically useful changes using molecular approaches.
Perhaps, in hindsight, it might have been expected that
the critical transcriptional changes required to achieve a
resolution equivalent to that of a global transcriptome
would reflect the importance of altered pathways already
known to be associated with different prognoses; i.e., cell
proliferation, hormone responsiveness, and ERB2 signaling
(Russnes et al., 2017). The 2016 ASCO guidelines state that
the clinical utility of the PAM50 test is limited to identi-
fying patients with ER/PR+, HER2- (and node)-negative
breast cancers, in conjunction with other pathological
variables, to guide decisions on the use of adjuvant sys-
temic therapy (Harris et al., 2016). This fits with the obser-
vation that all five of the transcriptionally defined sub-
groups are heterogeneous in terms of ER, PR, and HER2
expression.1680 Stem Cell Reports j Vol. 10 j 1676–1686 j June 5, 2018Most breast cancers classified transcriptionally as luminal
A or luminal B are ER+, the luminal B group being distin-
guished by a higher proliferative activity and a worse prog-
nosis. However, all groups include both ER+ and ER cases.
Similarly, 34% of the subgroup classified transcriptionally
as HER2-enriched are HER2 (Prat et al., 2013; Prat and
Perou, 2011). It is also important to note that none of the
available ‘‘omic’’ methods overcome the challenge of inter-
preting the potential significance of intra-tumor heteroge-
neities. This has recently been shown to extend to molecu-
lar classificationmethods with the demonstration of a 15%
re-allocation of luminal sub-groups from separate analyses
of two biopsies from the same tumor (Lopez-Knowles et al.,
2016).
The group identified transcriptionally as basal-like (Gus-
terson, 2009) consists primarily (80%) of cancers also
referred to as triple-negative because they do not contain
cells that express ER, PR, or HER2. Histologically, these
tumors are also generally already classified as high grade,
which is also predictive of a bad prognosis. A sub-group
of basal-like breast cancers (30% of triple-negative cancers)
named ‘‘Claudin-low’’ was identified in 2010 by their
elevated expression of markers indicative of epithelial to
mesenchymal transition, immune response genes, and
‘‘stem’’ cells (Prat et al., 2010).
However, in most basal-like breast cancers, expression of
two characteristic features of normal basal cells, CD10
and/or SMA, is low or absent (Livasy et al., 2006; Santagata
et al., 2014). This discrepancy has thus raised the question
of whether the cells in at least some of these tumors may
be more like certain luminal cells—either those in TDLUs
that produce some so-called basal CKs, or normal human
mammary cells defined phenotypically as luminal progeni-
tors by their co-expression of CD49f and EpCAM. As
discussedabove, this subsetof luminal cells alsocontaincells
with proliferative activity and other features thatmight pre-
dispose them to transformation (Kannan et al., 2013, 2014).
Alternatively, the lack of CD10 and SMA in basal-like breast
cancers could reflect the activation of mechanisms respon-
sible for the development of squamous metaplasia that
alsoderegulate control ofCKexpression (Gorski et al., 2010).
An important point to remember about all of the tran-
scriptionally defined sub-groups of human breast cancers
is their high degree of heterogeneity at both the cellular
and molecular level. This is evident not only between
patients with tumors of the same molecular sub-type
(Prat and Perou, 2011), and different regions of the same tu-
mor (Lopez-Knowles et al., 2016), but also in tumor sam-
ples from the same patient obtained at different times.
Thus, although transcriptional-based approaches offer
refined prognostication, they have not replaced reliance
on historic methods of anticipating treatment responses
to established therapies.
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tial to help address these issues as well as to identify new
therapeutic targets and treatment strategies. The advan-
tages of DNA sequencing for analyzing patients’ breast
cancers began to command significant attentionwhenmu-
tations in 40 genes and 73 combinations of mutated genes
were implicated from studies of 100 breast cancer genomes
(Stephens et al., 2012). Subsequent DNA analyses of 2,433
breast cancers enabled additional clinically relevant sub-
types to be identified (Pereira et al., 2016), and whole-
genome sequencing of 560 breast cancers revealed groups
defined by mutational profiles that had survival implica-
tions (Nik-Zainal et al., 2016). A recent review of the
stratification of breast cancers into both biologically and
clinically distinct sub-types has shown different classifiers
to be overlapping and hence complementary, probably
most usefully deployed in the future as integrated ap-
proaches (Russnes et al., 2017).
The fact thatmolecular analyses are becoming applicable
to single cells to resolve the heterogeneity of cellular
genomes within and between breast cancers is also of great
interest (Brady et al., 2017; Casasent et al., 2018; Gao et al.,
2017; Gupta and Somer, 2017). Analysis of circulating DNA
is likewise an important emerging technology to address
the same issue (Cheng et al., 2018; Zivanovic Bujak and
Dawson, 2018).
Human Breast Tumors with Basal Features
Sorlie et al. (2003) demonstrated that tumors arising in
mutant BRCA1 carriers are predisposed to display a
basal-like gene expression profile, although a majority
of the breast cancers arising in carriers of a BRCA1 muta-
tion have no unique histological features (Lakhani et al.,
2000). Nevertheless, breast cancers carrying BRCA1muta-
tions have come to be associated with a particular pathol-
ogy, referred to as medullary carcinoma, even though
only 13% of BRCA1-associated tumors have a clinically
recognized medullary or atypical medullary pathology
(Breast Cancer Linkage Consortium, 1997; Lakhani
et al., 1998). In addition, most medullary carcinomas
(77%) do not display a mutation in BRCA1. Human
breast cancers in which the BRCA1 gene is mutated
generally contain a high proportion of proliferating cells
that lack ER, PR, and HER2, and express basal CKs (CK5/
CK14 and CK17), but not CD10 or SMA. Together, these
features suggest a phenotype that is reminiscent of the
luminal progenitor subset. This inference is further sup-
ported by the finding that this compartment is selec-
tively enlarged in carriers of a mutant BRCA1 gene (Lim
et al., 2009), and shares properties of Brca1-associated
breast cancers produced in mouse models, as discussed
below (Molyneux et al., 2010; Molyneux and Smalley,
2011).Adenomyoepitheliomas with well-defined luminal as
well as basal components are extremely rare in humans,
and mostly benign (Hoda et al., 2014). Tumors composed
entirely of cells with myoepithelial features have also
been described and are referred to as myoepitheliomas
(Hoda et al., 2014). Squamous metaplasia (skin-like differ-
entiation with or without sebaceous elements) is some-
times evident in poorly differentiated human breast can-
cers classified as triple-negative. A lack of hormone
receptor expression, high proliferation, and an associated
expression of basal CKs in all of these squamous tumors
have contributed to their being classified as basal-like.
Genetically Engineered Mouse Models of Breast
Cancer with Basal Features
Mostmousemodels of breast cancer generate highly prolif-
erative tumors that are ER and HER2. They are thus
frequently referred to as models of basal-like human breast
cancers. However, given the known differences in the
stability of lineage programs in normal mammary cells
from the two species, and the different conditions required
to induce the proliferation of mouse and human basal cells
in vitro (Makarem et al., 2013a, 2013b), it may be antici-
pated that the same genetic perturbation may also not
have identical effects in both species.
An example is the reported ability of a targeted deletion
of Brca1 in ER luminal cells in Blg-Cre Brca1f/f p53+/
mice to produce mainly CK14+ tumors that resemble hu-
man BRCA1-deficient tumors, both at a pathological level
and as assessed by PAM50 (Molyneux et al., 2010; Moly-
neux and Smalley, 2011). However, normal mouse luminal
cells, unlike their human counterparts, do not express
CK14. Thus, the expression of CK14 in these malignant
Brca1/ mouse cells could argue against their luminal
cell origin, although this inference is supported by the
dependence of these tumors on expression of Kit (Regan
et al., 2012), which is a unique marker of the luminal pro-
genitor subset in both species. It is thus possible that CK14
expression becomes abnormally activated in Brca1-deleted
Blg-Cre Brca1f/f p53+/ mouse luminal cells. Interestingly,
in the absence of Blg-Cre, adenomyoepitheliomas and
adenosquamous carcinomas were obtained. Breast cancers
generated in a CK14-Cre Brac1f/f/p53f/f mouse were also
found to be similar to human BRCA1-deficient tumors,
with a minority being adenomyoepitheliomas (Liu et al.,
2007).
There are a growing number of other genetically engi-
neered tumor models in mice that bear some resemblance
to the rare recurrent human adenomyoepitheliomas and
frequently contain squamous elements. Examples include
mouse tumors arising as a result of the introduction of an
oncogenic PIK3CA (H1047R) gene (Koren et al., 2015;
Molyneux et al., 2010; Van Keymeulen et al., 2015) asStem Cell Reports j Vol. 10 j 1676–1686 j June 5, 2018 1681
Stem Cell Reports
Perspectivewell as Brca1 deletion. Targeted mutation of PIK3CA in
mouse luminal cells generates adenosquamous carcinomas
as well as adenomyoepitheliomas (Meyer et al., 2011, 2013)
with some resemblance to rare recurrent human adeno-
myoepitheliomas (Hoda et al., 2014). However, in the
mouse tumors, there is often a mixture of adenomyoepi-
thelioma and squamous elements not evident in similarly
classified human tumors. Mutations in PTEN in mice also
produce mammary adenomyoepitheliomas (Couto et al.,
2012; Dourdin et al., 2008) that are classified as benign
(Cardiff et al., 2000) and are part of the hamartoma spec-
trum associated with PTEN mutations.
In mice, adenosquamous tumors with squamous meta-
plasia have a clearly defined skin-like structure in some
areas, with expression of squamous CKs that include
CK5. Histologically, the squamous elements appear to be
derived from basal elements that produce bilayered glan-
dular structures as well as squamous metaplasia, often
within the same specimen. However, the basal cells in the
squamous areas lack SMA, whereas the glandular compo-
nents usually have a bilayered structure with an obvious
myoepithelial layer of cells expressing CK5, CK14, and
SMA (Koren et al., 2015; Van Keymeulen et al., 2015).
Adenomyoepithelial tumors produced in mice have a
very well-defined myoepithelial layer, with features sug-
gesting they are at the benign end of the spectrum with
either the presence or absence of SMA in the basal layer.
Nevertheless, their assessment with a mouse equivalent
of the PAM50, or other gene set used to classify human
breast cancers, yields a luminal-like designation, largely
due to their ER positivity. However, the fact that these
experimentally derived mouse tumors given such a desig-
nation have benign features points to the need for caution
in extrapolating similarities with human breast cancers
assigned the same transcriptional classification. A com-
pounding difficulty for the experimentalist is that the
mice in which such tumors arise often have to be sacrificed
before clear evidence ofmalignancy has appeared, thus pre-
cluding assessment of a pathobiology that might appear
after more prolonged tumor growth. It is also important
to appreciate that all of the abovemodels produce a diverse
range of tumor types.
These examples illustrate the restricted scope of current
mouse tumor models in recreating the spectrum of human
breast cancers defined as basal-like. Possible explanations
for this situation include species differences in the lineage
specificity expression of certain CKs. Nevertheless, produc-
tive uses of genetically defined mouse tumor models to
analyze treatment responses illustrate their power to reveal
programmatic changes in the gene expression profiles and
responses of the transformed cell populations produced
(Dine andDeng, 2013). An example is the ability of PIK3CA
to activate a multipotent differentiation program inmouse1682 Stem Cell Reports j Vol. 10 j 1676–1686 j June 5, 2018mammary cells that normally appear luminal lineage
restricted (Koren et al., 2015; Van Keymeulen et al., 2015).
Advantages and Caveats in Modeling the Genesis of
Human Breast Cancers
Avariety of immunodeficientmice that support the growth
of normal and transformed human cell transplants now
exist (Walsh et al., 2017). These include long-lived, but
highly immunodeficient, mice lacking all B, T, and natural
killer lineage cell types, and whose macrophages have a
compromised phagocytic function. Their use has now
enabled normal and malignant human mammary cells
with extensive in vivo regenerative activity to be partially
characterized (Eirew et al., 2008; Lim et al., 2009; Nguyen
et al., 2014a, 2014b). Such transplant experiments have
served as an important foundation formore recent analyses
of transplanted populations of patients’ breast cancer cells,
most notably to correlate the in vivo growth responses
obtained with the mutational status and/or treatment of
the transplanted cells (Bruna et al., 2016; Byrne et al.,
2017; Dobrolecki et al., 2016; Eirew et al., 2015; Gao
et al., 2015; Nguyen et al., 2014a).
Another approach to analyzing driver events in the pro-
cess of human mammary cell transformation exploits
similar xenotransplantation methods to identify tumors
created de novo by mutating mammary cells isolated
directly from normal human breast tissue. This strategy
combines the advantages historically exploited in geneti-
cally engineered mouse models of starting with defined
subsets of cells and then introducing known mutations
into them so that subsequent changes can then be tracked
over time. The use of normal human cells as the initial tar-
gets also bypasses the caveats of species differences
inherent in mouse models. The advent of lentiviral vectors
that can deliver multiple genetic payloads at high effi-
ciency into primary human mammary cell types has now
made this approach feasible, although the number of suc-
cessful models remains very limited (Keller et al., 2012;
Morel et al., 2017; Nguyen et al., 2015; Proia et al., 2011).
Underscoring the promise of this approach is the recent
discovery of the speed, reproducibility, and efficiency
with which serially transplantable human breast cancers
can now be produced from normal human mammary cells
transduced with KRASG12D (Nguyen et al., 2015). Interest-
ingly, the initial tumors obtained are polyclonal and
morphologically highly heterogeneous with no dominant
basal, basal-like, or luminal features evident from IHC ana-
lyses. In addition, no significant differences have been
found to date in the diversity of cell types they contain,
or their rate of growth or malignant progression when
derived separately from purified normal human luminal
progenitor or basal subsets. On the other hand, an impor-
tant observation has been the separate origin of the cells
Stem Cell Reports
Perspectivefrom either that are serially transplantable, suggesting this
latter property may be a delayed acquisition.
Conclusions
Most human cancers reflectmany of the distinguishing fea-
tures of the tissue fromwhich the cancer arose. Indeed, this
is generally the first line of their classification.Most human
cancers are also clonal (i.e., they arise from a single cell
within the tissue of origin) and show varying retention of
specific types of cells within that tissue despite a character-
istically perturbed differentiation process. These observa-
tions have prompted interest in identifying the cell of
origin of experimentally created breast cancers with the
expectation that the identification of critical retained
features might facilitate the discovery of new, more perva-
sively active treatments. At the same time, the most prom-
inent features of the malignant cells have oftenmistakenly
been assumed to reflect those of the cell of origin, as well as
those cells capable of sustaining the further growth of the
tumor. Chronic myeloid leukemia is a classic example for
which the prominent cell in the clone is a non-dividing
neutrophil, but the cell of origin is a multipotent cell that
also generates erythrocyte and platelets until all of those
pathways are suppressed in the terminal blast phase of
the disease (Clarke andHolyoake, 2017). The use of features
of the dominant population was similarly adopted when
the first transcriptome data for human breast cancers was
generated. But this operational terminology should not
be assumed to identify cell-type-specific differences in the
cell of origin, or even the point of differentiation blockade
(Stingl and Caldas, 2007; Visvader and Stingl, 2014).
Awareness of this situation has heightened interest in
defined models in which the process of tumorigenesis
can be followed in a forward fashion. At the same time, it
is becoming clear that such models require increasing
attention to be given to their characterization, particularly
in light of known discrepancies between the development
and differentiation of normal mouse and human mam-
mary cells. This includes a need for a comprehensive
examination of the pathological features of the tumors pro-
duced, as well as a need to couple molecular analyses to
functional measurements of growth potential.
Human breast cancers now described as basal-like are a
prime example of a group of human tumors where more
effective treatments and methods to identify earlier-stage
disease are badly needed. Experiments designed to infer
the evolution and potential origin of such tumors from
retrospective analysis of patient samples, as well as increas-
ingly powerful de novo models in either mouse or human
cells, offer complementary approaches, each with accom-
panying caveats and limitations. Nevertheless, the use of
more precise and consistent terminology, coupled with
increasing knowledge of the properties and regulation ofnormal human mammary cells, and increasingly refined
molecular and histopathological analyses of individual
cells and phenotypes, should advance the pace at which
critical new insights can be generated.
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